Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725309 | 0.87 | KMT2A (0.53) | ALDH1A1LMNASMN1; SMN2CNR2KMT2A | |
| SCHEMBL28452609 | 0.73 | KMT2A (0.52) | ALDH1A1LMNACNR2KMT2ASLC6A7 | |
| SCHEMBL21605339 | 0.72 | LMNA (0.66) | ALDH1A1LMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL1813422 | 0.72 | LMNA (0.66) | ALDH1A1LMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL6630730 | 0.70 | NTRK1 (0.43) | ALDH1A1SMN1; SMN2CNR2KMT2ASLC6A7 | |
| SCHEMBL5650614 | 0.70 | CLK4 (0.47) | ALDH1A1SMN1; SMN2KMT2AKDM4EHSD17B10 | |
| SCHEMBL25176183 | 0.69 | ELANE (0.46) | PKM | |
| SCHEMBL9125486 | 0.69 | CES2 (0.79) | ALDH1A1LMNASMN1; SMN2HSD11B1KMT2A | |
| Hydrochloric Acid SCHEMBL28747737 | 0.68 | CLK4 (0.46) | ALDH1A1SMN1; SMN2KMT2AKDM4EHSD17B10 | |
| SCHEMBL725082 | 0.68 | THRB (0.53) | ALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210308105-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ALDH1A1 209/4885LMNA 3427/4885SMN1; SMN2 3816/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ALDH1A1 209/4885LMNA 3427/4885SMN1; SMN2 3816/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | ALDH1A1 2765/4885LMNA 588/4885SMN1; SMN2 3405/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885LMNA 1128/4885SMN1; SMN2 1722/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ALDH1A1 209/4885LMNA 3427/4885SMN1; SMN2 3816/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ALDH1A1 209/4885LMNA 3427/4885SMN1; SMN2 3816/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | ALDH1A1 3603/4885LMNA 1035/4885SMN1; SMN2 2823/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ALDH1A1 209/4885LMNA 3427/4885SMN1; SMN2 3816/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | ALDH1A1 3603/4885LMNA 1035/4885SMN1; SMN2 2823/4885 |
| US-20210308105-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | ALDH1A1 3603/4885LMNA 1035/4885SMN1; SMN2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.